Tse‐I Lin

1.4k total citations
30 papers, 670 citations indexed

About

Tse‐I Lin is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Tse‐I Lin has authored 30 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 17 papers in Epidemiology and 10 papers in Molecular Biology. Recurrent topics in Tse‐I Lin's work include Hepatitis C virus research (20 papers), Hepatitis B Virus Studies (15 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Tse‐I Lin is often cited by papers focused on Hepatitis C virus research (20 papers), Hepatitis B Virus Studies (15 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Tse‐I Lin collaborates with scholars based in Sweden, Belgium and United States. Tse‐I Lin's co-authors include Oliver Lenz, Kenneth Simmen, Pierre Raboisson, Gregory Fanning, Thierry Verbinnen, Herman de Kock, Lotta Vrang, Michael Edlund, Annick Scholliers and Katrien Vermeiren and has published in prestigious journals such as Angewandte Chemie International Edition, Gastroenterology and PLoS ONE.

In The Last Decade

Tse‐I Lin

25 papers receiving 660 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tse‐I Lin Sweden	11	480	377	276	126	63	30	670
Peter T. Nower United States	14	767 1.6×	598 1.6×	360 1.3×	131 1.0×	86 1.4×	20	901
Yu-Ping Luong United States	8	429 0.9×	302 0.8×	218 0.8×	103 0.8×	42 0.7×	10	538
Tatyana Dekhtyar United States	16	619 1.3×	495 1.3×	453 1.6×	103 0.8×	98 1.6×	32	868
Roger Maurice Canada	11	475 1.0×	281 0.7×	223 0.8×	197 1.6×	33 0.5×	15	699
Rakesh Tripathi United States	20	1.0k 2.1×	859 2.3×	579 2.1×	270 2.1×	61 1.0×	43	1.5k
Meg Keilman United States	9	609 1.3×	482 1.3×	522 1.9×	319 2.5×	181 2.9×	12	1.1k
John P. Maxwell United States	8	212 0.4×	154 0.4×	107 0.4×	127 1.0×	79 1.3×	23	409
Kevin M. Cottrell United States	7	211 0.4×	153 0.4×	102 0.4×	173 1.4×	57 0.9×	21	413
S. Shane Taremi United States	11	359 0.7×	217 0.6×	159 0.6×	250 2.0×	17 0.3×	14	712
Julie Q. Hang United States	16	238 0.5×	228 0.6×	340 1.2×	257 2.0×	118 1.9×	20	718

Countries citing papers authored by Tse‐I Lin

Since Specialization

Citations

This map shows the geographic impact of Tse‐I Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tse‐I Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tse‐I Lin more than expected).

Fields of papers citing papers by Tse‐I Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tse‐I Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tse‐I Lin. The network helps show where Tse‐I Lin may publish in the future.

Co-authorship network of co-authors of Tse‐I Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Tse‐I Lin. A scholar is included among the top collaborators of Tse‐I Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tse‐I Lin. Tse‐I Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gane, Edward, Christian Schwabe, Min Wu, et al.. (2025). A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants. Antiviral Therapy. 30(6). 232118715–232118715.

Yuen, Man‐Fung, Kosh Agarwal, Alina Jucov, et al.. (2025). THU-261 Monotherapy with the novel capsid assembly modulator ALG- 000184 for up to 96 weeks results in profound and sustained HBV DNA suppression in untreated subjects with chronic HBV infection. Journal of Hepatology. 82. S836–S837.

Agarwal, Kosh, Edward Gane, Man‐Fung Yuen, et al.. (2024). WED-361 Dosing with the Capsid Assembly Modulator ALG-000184 in Untreated HBeAg Negative CHB Subjects Results in Potent Antiviral Effects Including Suppression of HBV DNA/RNA and Declines in HBcrAg Levels. Journal of Hepatology. 80. S806–S806.

Hou, Jinlin, Yanhua Ding, Junqi Niu, et al.. (2023). ALG-000184, a capsid assembly modulator, dosed with entecavir for up to 28 weeks is well tolerated and resulted in substantial declines in surface antigen levels in untreated Hepatitis B e antigen positive subjects with chronic hepatitis B. Journal of Hepatology. 78. S112–S113.

Gupta, Kusum, Megan Fitzgerald, Jin Tae Hong, et al.. (2023). Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liver. Journal of Hepatology. 78. S1029–S1029. 1 indexed citations

Fitzgerald, Megan, Kusum Gupta, Kha Le, et al.. (2022). The HBV siRNA, ALG-125755, demonstrates a favourable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model. Journal of Hepatology. 77. S846–S846. 1 indexed citations

Yuen, Man‐Fung, Kosh Agarwal, Edward Gane, et al.. (2022). Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B. Journal of Hepatology. 77. S835–S836. 8 indexed citations

Herschke, Florence, Chris Li, Ren Zhu, et al.. (2021). JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms. Antiviral Research. 196. 105196–105196. 10 indexed citations

Zhang, Qingling, Sandrine Vendeville, V. N. Serebryany, et al.. (2020). ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B. Journal of Hepatology. 73. S880–S881. 4 indexed citations

10.

Luong, Xuan G., Sarah Stevens, Andreas Jekle, et al.. (2020). Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLoS ONE. 15(12). e0240338–e0240338. 31 indexed citations

11.

Jonckers, Tim H. M., Abdellah Tahri, Leen Vijgen, et al.. (2016). Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2′-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3′-5′-Cyclic Phosphate Ester Prodrug of 2′-Deoxy-2′-Spirooxetane Uridine Triphosphate Useful for HCV Inhibition. Journal of Medicinal Chemistry. 59(12). 5790–5798. 18 indexed citations

12.

Berke, Jan Martin, Leen Vijgen, Sophie Lachau‐Durand, et al.. (2011). Antiviral Activity and Mode of Action of TMC647078, a Novel Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase. Antimicrobial Agents and Chemotherapy. 55(8). 3812–3820. 6 indexed citations

13.

Berke, Jan Martin, Denis Fenistein, Frederik Pauwels, et al.. (2010). Development of a high-content screening assay to identify compounds interfering with the formation of the hepatitis C virus replication complex. Journal of Virological Methods. 165(2). 268–276. 8 indexed citations

14.

Cummings, Maxwell D., Jimmy Lindberg, Tse‐I Lin, et al.. (2010). Innentitelbild: Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target (Angew. Chem. 9/2010). Angewandte Chemie. 122(9). 1552–1552. 1 indexed citations

15.

Cummings, Maxwell D., Jimmy Lindberg, Tse‐I Lin, et al.. (2010). Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target. Angewandte Chemie International Edition. 49(9). 1652–1655. 71 indexed citations

16.

Lin, Tse‐I, Oliver Lenz, Gregory Fanning, et al.. (2009). In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor. Antimicrobial Agents and Chemotherapy. 53(4). 1377–1385. 142 indexed citations

17.

Raboisson, Pierre, Tse‐I Lin, Herman de Kock, et al.. (2008). Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(18). 5095–5100. 18 indexed citations

18.

Liang, Yuqiong, Hisashi Ishida, Oliver Lenz, et al.. (2008). Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors. Gastroenterology. 135(5). 1710–1718.e2. 39 indexed citations

19.

Raboisson, Pierre, Oliver Lenz, Tse‐I Lin, et al.. (2007). Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(7). 1843–1849. 11 indexed citations

20.

Lin, Tse‐I, Vladimir D. Sled, Tomo̧ko Ohnishi, Axel Brennicke, & Lutz Grohmann. (1995). Analysis of the Iron-Sulfur Clusters Within the Complex I (NADH: Ubiquinone Oxidoreductase) Isolated from Potato Tuber Mitochondria. European Journal of Biochemistry. 230(3). 1032–1036. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact